The present and future of bispecific antibodies for cancer therapy
Bispecific antibodies (bsAbs) enable novel mechanisms of action and/or therapeutic
applications that cannot be achieved using conventional IgG-based antibodies …
applications that cannot be achieved using conventional IgG-based antibodies …
Bispecific antibodies in the treatment of multiple myeloma
AJ Devasia, A Chari, G Lancman - Blood Cancer Journal, 2024 - nature.com
The treatment paradigm in myeloma is constantly changing. Upfront use of monoclonal
antibodies like daratumumab along with proteasome inhibitors (PI) s, and immune …
antibodies like daratumumab along with proteasome inhibitors (PI) s, and immune …
Multiple myeloma, version 2.2024, NCCN clinical practice guidelines in oncology
SK Kumar, NS Callander, K Adekola… - Journal of the National …, 2023 - jnccn.org
The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several
new options. These include new combinations with second generation proteasome …
new options. These include new combinations with second generation proteasome …
IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies
BCMA-targeted bispecific antibodies (BiAb) are efficacious in relapsed/refractory multiple
myeloma; however, serious infections have emerged as important toxicities. In this …
myeloma; however, serious infections have emerged as important toxicities. In this …
Antibodies to watch in 2024
S Crescioli, H Kaplon, A Chenoweth, L Wang… - MAbs, 2024 - Taylor & Francis
ABSTRACT The 'Antibodies to Watch'article series provides an annual summary of
commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical …
commercially sponsored monoclonal antibody therapeutics currently in late-stage clinical …
ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells
L Carretero-Iglesia, OJ Hall, J Berret, D Pais… - Nature Cancer, 2024 - nature.com
Despite recent advances in immunotherapies targeting single tumor-associated antigens,
patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) …
patients with multiple myeloma eventually relapse. ISB 2001 is a CD3+ T cell engager (TCE) …
Real-world analysis of teclistamab in 123 RRMM patients from Germany
C Riedhammer, F Bassermann, B Besemer… - Leukemia, 2024 - nature.com
Teclistamab, a B-cell maturation antigen (BCMA)× CD3 directed bispecific antibody, has
shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with …
shown high response rates and durable remissions in the MAJESTEC-1 trial in patients with …
Bispecific T cell engager therapy for refractory rheumatoid arthritis
Bispecific T cell engagers (BiTEs) kill B cells by engaging T cells. BiTEs are highly effective
in acute lymphoblastic leukemia. Here we treated six patients with multidrug-resistant …
in acute lymphoblastic leukemia. Here we treated six patients with multidrug-resistant …
Multiple myeloma: signaling pathways and targeted therapy
Q Lu, D Yang, H Li, T Niu, A Tong - Molecular Biomedicine, 2024 - Springer
Multiple myeloma (MM) is the second most common hematological malignancy of plasma
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …
cells, characterized by osteolytic bone lesions, anemia, hypercalcemia, renal failure, and the …
Engineered T cells secreting anti-BCMA T cell engagers control multiple myeloma and promote immune memory in vivo
L Díez-Alonso, A Falgas, J Arroyo-Ródenas… - Science translational …, 2024 - science.org
Multiple myeloma is the second most common hematological malignancy in adults and
remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy …
remains an incurable disease. B cell maturation antigen (BCMA)–directed immunotherapy …